228 related articles for article (PubMed ID: 31818534)
1. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine.
Tavares-Da-Silva F; Co MM; Dessart C; Hervé C; López-Fauqued M; Mahaux O; Van Holle L; Stegmann JU
Vaccine; 2020 Apr; 38(18):3489-3500. PubMed ID: 31818534
[TBL] [Abstract][Full Text] [Related]
2. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
[TBL] [Abstract][Full Text] [Related]
5. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
[TBL] [Abstract][Full Text] [Related]
6. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
Stefanizzi P; Moscara L; Palmieri C; Martinelli A; Di Lorenzo A; Venerito V; Germinario CA; Tafuri S
Vaccine; 2024 Apr; 42(12):2966-2974. PubMed ID: 38582693
[TBL] [Abstract][Full Text] [Related]
8. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
Willis ED; Woodward M; Brown E; Popmihajlov Z; Saddier P; Annunziato PW; Halsey NA; Gershon AA
Vaccine; 2017 Dec; 35(52):7231-7239. PubMed ID: 29174682
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
[TBL] [Abstract][Full Text] [Related]
10. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.
Hesse EM; Shimabukuro TT; Su JR; Hibbs BF; Dooling KL; Goud R; Lewis P; Ng CS; Cano MV
MMWR Morb Mortal Wkly Rep; 2019 Feb; 68(4):91-94. PubMed ID: 30703077
[TBL] [Abstract][Full Text] [Related]
11. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
12. Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients.
Ocran-Appiah J; Boutry C; Hervé C; Soni J; Schuind A;
Vaccine; 2021 Jan; 39(1):6-10. PubMed ID: 33277059
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
Parikh R; Singer D; Chmielewski-Yee E; Dessart C
Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254
[TBL] [Abstract][Full Text] [Related]
14. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
15. Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology.
Tavares-Da-Silva F; Mahaux O; Van Holle L; Haguinet F; Seifert H; Stegmann JU
Drug Saf; 2020 Dec; 43(12):1223-1234. PubMed ID: 32862397
[TBL] [Abstract][Full Text] [Related]
16. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients.
Racine É; Gilca V; Amini R; Tunis M; Ismail S; Sauvageau C
Vaccine; 2020 Sep; 38(40):6205-6214. PubMed ID: 32788132
[TBL] [Abstract][Full Text] [Related]
17. Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
Ali SO; Dessart C; Parikh R
Vaccine; 2024 Mar; 42(8):2026-2035. PubMed ID: 38423814
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis.
Xia Y; Zhang X; Zhang L; Fu C
Front Immunol; 2022; 13():978203. PubMed ID: 36248796
[TBL] [Abstract][Full Text] [Related]
19. Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance.
Fiore J; Co-van der Mee MM; Maldonado A; Glasser L; Watson P
Ther Adv Vaccines Immunother; 2021; 9():25151355211057479. PubMed ID: 35005428
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
Hastie A; Catteau G; Enemuo A; Mrkvan T; Salaun B; Volpe S; Smetana J; Rombo L; Schwarz T; Pauksens K; Hervé C; Bastidas A; Schuind A
J Infect Dis; 2021 Dec; 224(12):2025-2034. PubMed ID: 32502272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
